Search results
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 9 hours agoOne of the drugs, the lung cancer treatment Tagrisso, has already exceeded $5 billion in annual...
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 2 days agoMerck MRK boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda...
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Finance· 4 days agoMerck MRK will discontinue the Keytruda plus vibostolimab co-formulation arm of a phase III melanoma...
Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials
Investing.com· 6 days agoAIM ImmunoTech (NYSE: AIM ) Inc. (NYSE American: AIM) provided an optimistic update during its first...
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Zacks via Yahoo Finance· 6 days agoHere we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK),...
Americans Are Spending the Most Money on These 25 Prescription Drugs
Healthline· 6 days agoThe diabetes and weight loss medication semaglutide (Ozempic, Wegovy, and Rybelsus) topped the list....
Cramer says these 10 stocks helped the Dow briefly crack 40,000
CNBC· 5 days agoCNBC's Jim Cramer listed ten stocks that helped the Dow Jones Industrial Average briefly top 40,000 on Thursday, a new high for the index. "To me, this list is emblematic of the fact that we ...
The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E
Zacks via Yahoo Finance· 6 days agoWith continued label expansion into new indications, particularly earlier-stage launches, Keytruda...
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Benzinga via AOL· 6 days agoOn Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical...
Perioperative Nivolumab Boosts EFS in Resectable Lung Cancer
MedPage Today· 7 days agoCheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death